Original ResearchSimvastatin plus capecitabine–cisplatin versus placebo plus capecitabine–cisplatin in patients with previously untreated advanced gastric cancer: A double-blind randomised phase 3 study
Introduction
Gastric cancer (GC) is the second most common cause of cancer-related death world-wide and the most frequently occurring malignancy in Korea [1], [2]. Although most patients with the early stage disease receive surgical resection with curative intent, more than 60% of these patients have a high rate of locoregional as well as distant recurrence [3], [4], [5]. For patients with unresectable, recurrent or advanced gastric cancer (AGC), systemic chemotherapy can improve survival and symptom control. Combination chemotherapy improves treatment outcomes compared with mono-chemotherapy or best supportive care (BSC) in patients with advanced gastric cancer [6]. Although there is no internationally accepted standard of first line chemotherapy regimen, either infusional or oral fluoropyrimidine plus platinum compound is now regarded as a standard regimen. However, more than half of patients with AGC who receive standard chemotherapy did not achieve response, and even in responders, the duration of response was as short as a few months [7].
Statins are synthetic 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors which are commonly used drugs for treatment of hypercholesterolemia. Statins inhibit the rate limiting step of the mevalonate pathway in which mevalonic acid is the precursor in the biosynthesis of isoprenoid molecules such as cholesterol, dolichol and ubiquinone. Mevalonate-derived prenyl groups, farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP), facilitate essential intracellular functions of various proteins [8], [9], [10]. FFP and GGPP are essential substrates for posttranslational modifications of rat sarcoma viral oncogene homologue (RAS) and ras homologue gene family, member A (RHOA), which play an important role in cellular proliferation. Based on the effect of statin on posttranscriptional modifications of RAS and RHOA, the antitumour effect of statins has been suggested in various cancer cell lines [11], [12], [13]. However, most studies used high concentrations of statin which was not feasible for human use to demonstrate an antitumour effect [14], [15], [16]. Recently, we demonstrated antitumour effect of simvastatin using a dose level that is equivalent to cardiovascular therapeutic dose level in humans [17], [18]. In addition, other studies reported that low concentrations of statins induced apoptosis of microvascular endothelial cells and lowered vascular endothelial growth factor (VEGF) serum levels implicating a possible antiangiogenic role in cancer treatment [19], [20]. Hence, our group conducted clinical trials for chemotherapy plus low-dose simvastatin in various cancer types and demonstrated that there were no additive side-effects [18], [21].
In the placebo-controlled, double-blinded, simvastatin in combination with capecitabine–cisplatin (XP) in advanced gastric cancer study, we aimed to assess efficacy and safety of the addition of simvastatin to first line capecitabine–cisplatin (XP) chemotherapy in patients with unresectable advanced or metastatic gastric adenocarcinoma.
Section snippets
Study design
This study was a prospective, random-assignment, double-blinded, placebo-controlled phase III clinical trial. The protocol was approved at each participating site by an institutional review board. This study was registered with ClinicalTrials.gov, identifier: NCT01099085 and conducted according to the Declaration of Helsinki and all of its amendments. All patients provided written informed consent before study enrolment.
Patients were assigned (1:1 ratio) to each treatment group by using
Patients
Between February 2009 and November 2012, 244 patients were enrolled and assigned to treatment groups (120 simvastatin, 124 placebo) at nine centres in KOREA (Fig. 1). Patients’ characteristics were well balanced between treatment groups (Table 1).
Treatment
Median treatment duration was 4.43 months in the simvastatin plus XP group and 4.50 months in the placebo plus XP group without significant difference. Median dose intensities (i.e. actual dose administered divided by planned dose) were 93.4% and 90.5%
Discussion
This study is the first phase III evaluation of HMG-CoA reductase inhibitor, simvastatin, with chemotherapy in advanced gastric adenocarcinoma. We observed that the addition of simvastatin to capecitabine–cisplatin (XP) did not improve PFS compared with XP alone. Therefore, the primary end-point was not met. PFS in the simvastatin plus XP (median 5.2 months) was not improved compared with results from previous randomised doublet or triplet chemotherapy regimens in first line setting of AGC
Conflict of interest statement
None declared.
Acknowledgments
We acknowledge the CJ Corp. who kindly donated simvastatin and placebo for the study.
This work was supported by Grants from the Korean Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (A102166).
This study was supported by an Intramural grant from Samsung Medical Center (CRS109613). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.
References (30)
- et al.
Patterns of failure following curative resection of gastric carcinoma
Int J Radiat Oncol Biol Phys
(1990) - et al.
Lovastatin-induced RhoA modulation and its effect on senescence in prostate cancer cells
Biochem Biophys Res Commun
(2006) - et al.
Plasma levels of vascular endothelial growth factor and its soluble receptor (SFlt-1) in essential hypertension
Am J Cardiol
(2001) - et al.
The potential of statins as part of anti-cancer treatment
Eur J Cancer
(2005) - et al.
Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
Am J Cardiol
(1998) - et al.
Inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase pathway induces p53-independent transcriptional regulation of p21(WAF1/CIP1) in human prostate carcinoma cells
J Biol Chem
(1998) - et al.
Lovastatin induces growth inhibition and apoptosis in human malignant glioma cells
Biochem Biophys Res Commun
(1994) - et al.
Trends of stomach cancer mortality in Eastern Asia in 1950–2004: comparative study of Japan, Hong Kong and Singapore using age, period and cohort analysis
Int J Cancer
(2012) - et al.
Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2009
Cancer Res Treat
(2012) - et al.
Recurrence following curative resection for gastric carcinoma
Br J Surg
(2000)
Patterns of failure in gastric carcinoma after D2 gastrectomy and chemoradiotherapy: a radiation oncologist’s view
Br J Cancer
Chemotherapy for advanced gastric cancer
Cochrane Database Syst Rev
The role of chemotherapy in the current treatment of gastric cancer
Gastric Cancer
Protein lipidation in cell signaling
Science
Regulation of the mevalonate pathway
Nature
Cited by (76)
Unraveling lipid metabolism reprogramming for overcoming drug resistance in melanoma
2024, Biochemical PharmacologyMetabolic switch in cancer – Survival of the fittest
2023, European Journal of CancerCitation Excerpt :In retrospective studies, statin treatment in combination with first-line chemotherapy prolonged the survival in patients with multiple CRC [128], metastatic pancreatic cancer [129], and myeloma [130]. In contrast, phase 3 trials in patients with SCLC [131], CRC [132], HCC [133], or gastric cancer [134] did not show any additional benefit from simvastatin or pravastatin indicating that the strategies inhibiting cholesterol biosynthesis may be neutralised by dietary lipids (statin trials reviewed in Ref. [135]). Sterol regulatory element-binding protein 1 (SREBP-1) is an important regulator of lipogenesis and a key player in converting carbohydrates into FA and triglyceride storage in cytoplasmic droplets.
Repurposing of metabolic drugs and mitochondrial modulators as an emerging class of cancer therapeutics with a special focus on breast cancer
2022, Advances in Cancer Biology - MetastasisProtein lipidation in health and disease: molecular basis, physiological function and pathological implication
2024, Signal Transduction and Targeted Therapy
- 1
These two authors contributed equally.